1 week Ago By Defense World Staff
JPMorgan Chase & Co. cut its stake in shares of Doximity, Inc. (NASDAQ:DOCS – Free Report) by 10.
7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 444,596 shares of the company’s stock after selling 53,460 shares during the period. JPMorgan Chase & Co.
owned about 0.24% of Doximity worth $23,737,000 at the end of the most recent reporting period. Several other large investors have also recently added to or reduced their stakes in the stock.
Lord Abbett & CO. LLC acquired a new stake in shares of Doximity during the 3rd quarter valued at $29,453,000. Wilmington Savings Fund Society FSB acquired a new stake in Doximity during the third quarter valued at $24,691,000.
Vanguard Group Inc. grew its stake in Doximity by 4.5% in the fourth quarter.
Vanguard Group Inc. now owns 11,203,569 shares of the company’s stock valued at $598,159,000 after purchasing an additional 485,102 shares in the last quarter. Geode Capital Management LLC increased its position in Doximity by 19.
8% in the 3rd quarter. Geode Capital Management LLC now owns 2,856,984 shares of the company’s stock worth $124,503,000 after purchasing an additional 472,565 shares during the last quarter. Finally, Retirement Systems of Alabama increased its position in Doximity by 254.
3% in the 3rd quarter. Retirement Systems of Alabama now owns 534,256 shares of the company’s stock worth $23,278,000 after purchasing an additional 383,480 shares during the last quarter. Institutional investors and hedge funds own 87.
19% of the company’s stock. Insider Transactions at DoximityIn related news, Director Timothy S. Cabral sold 20,000 shares of the firm’s stock in a transaction on Monday, February 3rd.
The stock was sold at an average price of $57.62, for a total value of $1,152,400.00.
Following the completion of the transaction, the director now directly owns 6,360 shares of the company’s stock, valued at $366,463.20. This trade represents a 75.
87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 37.
40% of the stock is owned by insiders. Analyst Upgrades and DowngradesSeveral equities research analysts recently commented on the company. Wells Fargo & Company reissued an “equal weight” rating on shares of Doximity in a research note on Friday, February 7th.
Piper Sandler raised shares of Doximity from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $31.00 to $78.00 in a research note on Friday, February 7th.
Leerink Partners raised shares of Doximity from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $60.00 to $90.00 in a research report on Friday, February 7th.
Canaccord Genuity Group boosted their price target on Doximity from $60.00 to $71.00 and gave the stock a “hold” rating in a research report on Friday, February 7th.
Finally, Raymond James reissued an “outperform” rating and set a $83.00 price objective (up previously from $65.00) on shares of Doximity in a report on Friday, February 7th.
Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $64.22.
View Our Latest Stock Report on DoximityDoximity Stock Up 9.6 %DOCS stock opened at $55.59 on Thursday.
The business’s 50-day simple moving average is $65.02 and its 200 day simple moving average is $55.34.
The company has a market cap of $10.38 billion, a PE ratio of 55.59, a price-to-earnings-growth ratio of 4.
10 and a beta of 1.41. Doximity, Inc.
has a twelve month low of $22.96 and a twelve month high of $85.21.
Doximity Company Profile (Free Report)Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.Featured StoriesFive stocks we like better than DoximityStock Splits, Do They Really Impact Investors?Quantum Computing: The $6.
5 Billion Opportunity You Can’t IgnoreStock Average Calculator Are Tariffs Threatening Disney’s Comeback Story?What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole StoryIs Alphabet a Generational Buying Opportunity at These Levels?.
